Back to results
US 12,570,713 B2Granted
High-affinity TCR for recognizing AFP antigen
AssigneeXlifesc, Ltd.
InventorsYi Li, Xiaolin Li
Life of this patent
Estimating the term…
Abstract
Provided in the present invention is a T-cell receptor (TCR) having the characteristic of binding a FMNKFIYEI-HLA A0201 complex. The binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 5 times that of a wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Further provided in the present invention is a fusion molecule of the TCR with a therapeutic agent. The TCR may be used alone or in combination with the therapeutic agent, so as to target a tumor cell presenting the FMNKFIYEI-HLA A0201 complex.
Claims19
A T cell receptor (TCR), wherein the T cell receptor has an activity of binding FMNKFIYEI(SEQ ID NO:
- 33)-HLA A0201 complex, and the T cell receptor comprises a TCRα chain variable domain and a TCRβ chain variable domain, wherein the TCRα chain variable domain comprises 3 CDR regions, which are CDR1α, CDR2α and CDR3α, and the TCRβ chain variable domain comprises 3 CDR regions, which are CDR1β, CDR2β and CDR3β, wherein the CDR1α, CDR2α, CDR3α, CDR1β, CDR2β and CDR3β of the TCR are shown in the following CDR NO:
- 1, 3, 6, 7, 9, 10, 12 or 13
- CDR No.
- CDR1α
- CDR2α
- CDR3α
- 1
- DSAIYN
- IQSSQRE
- AVDSGGSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 53)
- 3
- DSAIYN
- IQSSQRE
- AVDGADSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 41)
- 6
- DSAIYN
- IQSSQRE
- AVDSHPSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 44)
- 7
- DSAIYN
- IQSSQRE
- AVDAAQSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 45)
- 9
- DSAIYN
- IQSSQRE
- AVDWHPSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 47)
- 10
- DSAIYN
- IQSSQRE
- AVDSQDSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 48)
- 12
- DSAIYN
- IQSSQRE
- AVDTMDSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 50)
- 13
- DSAIYN
- IQSSQRE
- AVDHHPSNYKLT
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 34)
- NO:
- 35)
- NO:
- 51)
- CDR No.
- CDR1β
- CDR2β
- CDR3β
- 1
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 3
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 6
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 7
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 9
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 10
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 12
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID NO:
- 39)
- NO:
- 37)
- NO:
- 38)
- 13
- SGHVS
- FQNEAQ
- ASSLFGQGREKLF
- (SEQ ID
- (SEQ ID
- (SEQ ID
- NO:
- 37)
- NO:
- 38)
- NO:
- 39).
208 more elements
Dependencies are inferred from the claim text.